Alteogen, 'Upside Still Ample' Stock Price at 127,200 Won (6.89%)

Alteogen is trading at 127,200 KRW as of 2:32 PM on the 6th, up 6.89% from the previous day. The trading volume is 2,385,755 shares, which is 103.45% of the previous day's volume. Alteogen is known as a biosimilar developer.

On May 6, Lee Dong-geon, a researcher at Shinhan Financial Investment, stated, "Multiple Hybrozyme platform technology export contracts are expected this year. It is judged that technology transfers are currently being discussed with several global pharmaceutical companies. In particular, on March 24, Alteogen confirmed through a PCT international patent application that it is developing a subcutaneous injection formulation of the immuno-oncology drug ‘Keytruda’. Considering the expansion potential and sales scale of Keytruda as an immuno-oncology drug, contracts worth at least 2.5 trillion KRW are expected. The stock price does not reflect this potential value. Hybrozyme alone could generate over 2 trillion KRW this year." He set Alteogen’s target price at 140,000 KRW.

Over the past five days, individual investors have net bought 9,931 shares of Alteogen, while foreigners and institutions have net sold 44,597 shares and net bought 11,212 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.